Genomic sequencing Assessment of 733 HER2-amplified Most important and metastatic breast tumours disclosed major enrichment of mutations that activate RAS–MAPK signalling in State-of-the-art tumours taken care of with prior anti-HER2 therapies121. These mutations, such as NF1 and HER2 activating mutations, lead to resistance to tucatinib and neratinib. Angiosarcoma. This uncommon https://www.directivepublications.org/journal-of-clinical-breast-cancer/